Lupin Limited strengthens diabetes portfolio with acquisition of three key trademarks from Boehringer Ingelheim International GmbH
Acquiring Company
Lupin
Acquired Company
Boehringer Ingelheim
Ingelheim am RheinBiotechnologyHealth CareMedicalPharmaceuticalpharmaceuticalsPharmaceuticalpharmaceuticalsDescription
Lupin Limited has announced the acquisition of three anti-diabetes trademarks—Gibtulio, Gibtulio Met, and Ajaduo—from Boehringer Ingelheim International GmbH. This strategic move aims to enhance Lupin's position in the diabetes care market and offer a broader range of treatment options to Indian patients dealing with Type 2 diabetes.
Quick answer
Lupin is acquiring Boehringer Ingelheim, announced December 15, 2024.
- How much did Lupin pay for Boehringer Ingelheim?
- The deal value was not disclosed.
- What does Lupin do?
- Lupin is a Mumbai-based pharma major dedicated to advancing medical science and improving patient lives globally.
- Where are Lupin and Boehringer Ingelheim based?
- Boehringer Ingelheim is based in Ingelheim am Rhein, Rhineland-Palatinate, Germany.
- Who are the decision-makers at Lupin?
- Fundz holds 3 contacts at Lupin. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Medical and Pharmaceutical
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- Cycle Pharmaceuticals completes acquisition of Banner Life Sciences, LLC to expand MS product portfolio (January 13, 2025)
- Vivo Infusion completes acquisition of Neurology Institute of San Antonio and Vista Infusions to expand infusion services (January 9, 2025)
- Eton Pharmaceuticals completes acquisition of Galzin® (zinc acetate) from Teva Pharmaceuticals USA, Inc. to advance treatment for Wilson Disease (January 5, 2025)
- Boston Scientific completes acquisition of Axonics, Inc. to expand into sacral neuromodulation (November 15, 2024)
- ActiGraph completes acquisition of Biofourmis Connect to enhance digital health solutions (January 7, 2025)
- OraSure Technologies completes acquisition of Sherlock Biosciences, Inc. to expand its innovation pipeline in molecular testing market (December 19, 2024)
Who to call at Lupin, and when
When Lupin changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Lupin raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Lupin, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Lupin. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Lupin makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Boehringer Ingelheim?
Boehringer Ingelheim was acquired by Lupin. The deal was reported on December 15, 2024. Lupin is a Mumbai-based pharma major dedicated to advancing medical science and improving patient lives globally. Lupin is privately held and operates in Biotechnology.
When did Lupin acquire Boehringer Ingelheim?
Lupin's acquisition of Boehringer Ingelheim was reported on December 15, 2024. Lupin Limited has announced the acquisition of three anti-diabetes trademarks—Gibtulio, Gibtulio Met, and Ajaduo—from Boehringer Ingelheim International GmbH. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Boehringer Ingelheim do?
Boehringer Ingelheim International GmbH is a multinational pharmaceutical company that has transferred the rights of three anti-diabetes trademarks—Gibtulio, Gibtulio Met, and Ajaduo—to Lupin Limited. It is privately held, operating in Pharmaceutical, and is based in Ingelheim am Rhein.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.